Second-line myelofibrosis treatment – the potential of JAK2 inhibitor NS-018
Making the market more competitive - the potential benefit of biosimilars
Can the dream of affordable cancer care come true?
Comparison of native vs pegylated asparaginase for HR Ph chromosome-negative ALL
The rising cost of drugs and how to address it